aevX Bio SA is a Swiss biotech start-up advancing a best-in-class long-acting local therapy for androgenetic alopecia, designed to maximize scalp efficacy while minimizing systemic exposure.
Products, services, technology
Our lead candidate, AV-1, is designed for the treatment of androgenetic alopecia by enabling sustained local delivery of androgen-modulating agents to the scalp, thereby maximizing local therapeutic effect while keeping systemic exposure close to baseline.
Cooperation possibilities
We seek strategic collaborations supporting our path from preclinical validation to Series A and toward pivotal trials. Therefore, we engage in partnerships with strategic pharma companies as well as suppliers for formulation, CMC, preclinical/clinical development and research organizations.
- http://www.aevxbio.com
- +41 79 525 66 88
- Send an email
- Glen George
Some insights
Hair loss affects 50% of men and 40% of women, carrying a high psychological burden. By providing a safe, long-acting solution, we reclaim quality of life and self-esteem for millions without forcing a choice between their hair and their health or mental well-being.
We are proud to be connecting the dots between known science and smart delivery to tackle a massive, underestimated market with the potential to establish a safer new standard of care.
We admire biotech teams that combine scientific rigor, patient focus and execution discipline. Especially founders who translate strong science into practical therapies that solve real unmet needs.
The team couples hands on bench to bedside drug development leadership with disciplined operating and financial execution as well as business development and entrepreneurship, supported by a strong network and a MAB. Additionally, the team integrates contracted expertise (IP, Regulatory).
By connecting us with smart capital, dermatology KOLs, translational partners, GMP/CMC experts and biotech operators who can help accelerate AV-1 from preclinical to clinical development.
We would like to connect with seed and strategic investors, family offices, CVC/VC funds, dermatology experts, CDMOs, formulation and CMC specialists, clinical development partners, and pharma partners in dermatology.
